Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

被引：15

作者：

Luo, Shuang ^{[1
,2
,3
,4
]}

Jiang, Yu ^{[5
]}

Zheng, Anfu ^{[1
,2
,3
]}

Zhao, Yueshui ^{[1
,2
,3
]}

Wu, Xu ^{[1
,2
,3
]}

Li, Mingxing ^{[1
,2
,3
]}

Du, Fukuan ^{[1
,2
,3
]}

Chen, Yu ^{[1
,2
,3
]}

Deng, Shuai ^{[1
,2
,3
]}

Chen, Meijuan ^{[1
,2
,3
]}

Li, Wanping ^{[1
,2
,3
]}

Li, Xiaobing ^{[1
,2
,3
]}

Gu, Li ^{[1
,2
,3
]}

Sun, Yuhong ^{[1
,2
,3
]}

Xiao, Zhangang ^{[2
,6
]}

Shen, Jing ^{[1
,2
,3
]}

机构：

[1] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China

[2] Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China

[3] South Sichuan Inst Translat Med, Luzhou, Peoples R China

[4] Second Peoples Hosp Jiangyou, Dept Pharm, Mianyang, Peoples R China

[5] Peoples Hosp Wusheng, Dept Pharm, Guangan, Peoples R China

[6] Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

hypoxia-inducible factors; breast cancer; drug delivery systems; tumor microenvironment; angiogenesis; glycolysis; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELL; TUMOR ANGIOGENESIS; FACTOR-I; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA HIF-1-ALPHA; ANTIANGIOGENIC THERAPY; ANTICANCER ACTIVITY; AEROBIC GLYCOLYSIS; MASTER REGULATORS; PYRUVATE-KINASE;

D O I：

10.3389/fphar.2022.1064661

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.

引用

页数：20

共 140 条

[21] Self-assembled hyaluronic acid nanoparticles for active tumor targeting [J].

Choi, Ki Young ;

Chung, Hyunjin ;

Min, Kyung Hyun ;

Yoon, Hong Yeol ;

Kim, Kwangmeyung ;

Park, Jae Hyung ;

Kwon, Ick Chan ;

Jeong, Seo Young .

BIOMATERIALS, 2010, 31 (01) :106-114

[22] A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells [J].

Chou, Chih-Chien ;

Chuang, Hsaio-Ching ;

Salunke, Santosh B. ;

Kulp, Samuel K. ;

Chen, Ching-Shih .

ONCOTARGET, 2015, 6 (10) :8271-8285

[23] The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth [J].

Christofk, Heather R. ;

Vander Heiden, Matthew G. ;

Harris, Marian H. ;

Ramanathan, Arvind ;

Gerszten, Robert E. ;

Wei, Ru ;

Fleming, Mark D. ;

Schreiber, Stuart L. ;

Cantley, Lewis C. .

NATURE, 2008, 452 (7184) :230-U74

[24] Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia [J].

Conley, Sarah J. ;

Gheordunescu, Elizabeth ;

Kakarala, Pramod ;

Newman, Bryan ;

Korkaya, Hasan ;

Heath, Amber N. ;

Clouthier, Shawn G. ;

Wicha, Max S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (08) :2784-2789

[25] Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1α and c-myc [J].

Cui, Jianxiu ;

Jiang, Hongchuan .

MEDICINE, 2019, 98 (40)

[26] Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator [J].

Darbeheshti, Farzaneh ;

Mahdiannasser, Mojdeh ;

Noroozi, Zahra ;

Firoozi, Zahra ;

Mansoori, Behnam ;

Daraei, Abdolreza ;

Bastami, Milad ;

Nariman-Saleh-Fam, Ziba ;

Valipour, Elahe ;

Mansoori, Yaser .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (24) :11322-11332

[27] HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs) [J].

De Francesco, Ernestina Marianna ;

Lappano, Rosamaria ;

Santolla, Maria Francesca ;

Marsico, Stefania ;

Caruso, Arnaldo ;

Maggiolini, Marcello .

BREAST CANCER RESEARCH, 2013, 15 (04)

[28] HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer [J].

de Heer, Ellen C. ;

Jalving, Mathilde ;

Harris, Adrian L. .

JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (10) :5074-5087

[29] Leukocyte trafficking in tumor microenvironment [J].

Del Prete, Annalisa ;

Schioppa, Tiziana ;

Tiberio, Laura ;

Stabile, Helena ;

Sozzani, Silvano .

CURRENT OPINION IN PHARMACOLOGY, 2017, 35 :40-47

[30] Salinomycin inhibits breast cancer progression via targeting HIF-1α/VEGF mediated tumor angiogenesis in vitro and in vivo [J].

Dewangan, Jayant ;

Srivastava, Sonal ;

Mishra, Sakshi ;

Divakar, Aman ;

Kumar, Sadan ;

Rath, Srikanta Kumar .

BIOCHEMICAL PHARMACOLOGY, 2019, 164 :326-335

← 1 2 3 4 5 6 7 8 9 10 →